^
    5d
    IMPEDE: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Medical College of Wisconsin | Recruiting --> Active, not recruiting | N=53 --> 28 | Trial completion date: Jan 2027 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Apr 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    pomalidomide • Sarclisa (isatuximab-irfc) • Empliciti (elotuzumab)
    17d
    EMAT: Elimination of Minimal Residual Disease After Transplant (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Medical College of Wisconsin | Recruiting --> Active, not recruiting
    Enrollment closed • Minimal residual disease
    |
    clonoSEQ
    |
    lenalidomide • Sarclisa (isatuximab-irfc) • dexamethasone injection
    28d
    NCI-2023-09969: Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, Elvira Umyarova | Trial completion date: Jan 2026 --> Aug 2026 | Trial primary completion date: Jan 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    SLAMF7 (SLAM Family Member 7)
    |
    cyclophosphamide • Sarclisa (isatuximab-irfc) • Hemady (dexamethasone tablets) • UD TGFbetai NK cells
    1m
    Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P2, N=12, Recruiting, Memorial Sloan Kettering Cancer Center | N=25 --> 12
    Enrollment change
    |
    Sarclisa (isatuximab-irfc)
    1m
    Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Emory University | Trial primary completion date: Jul 2025 --> May 2026
    Trial primary completion date
    |
    bortezomib • cyclophosphamide • Sarclisa (isatuximab-irfc)
    2ms
    GRAAL-2024: A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2/3, N=1200, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Iclusig (ponatinib) • Blincyto (blinatumomab) • Sarclisa (isatuximab-irfc)
    2ms
    Single-molecule localization microscopy reveals the molecular organization of endogenous membrane receptors. (PubMed, Sci Adv)
    To demonstrate the usefulness of the method for immunotherapy applications, we investigated the interaction of primary multiple myeloma cells with the therapeutic monoclonal antibodies daratumumab and isatuximab and a polyclonal anti-CD38 antibody. Our approach might lay the foundation for improved personalized diagnostics and treatment with therapeutic antibodies.
    Journal
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD69 (CD69 Molecule)
    |
    Darzalex (daratumumab) • Sarclisa (isatuximab-irfc)
    2ms
    GMMG-HD7: Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) (clinicaltrials.gov)
    P3, N=662, Active, not recruiting, University of Heidelberg Medical Center | Trial completion date: Mar 2027 --> Jun 2028 | Trial primary completion date: May 2025 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • doxorubicin hydrochloride • cyclophosphamide • dexamethasone • Sarclisa (isatuximab-irfc) • dexamethasone injection
    2ms
    A multicenter prospective randomized controlled study of quadruplet regimen in newly diagnosed transplant-ineligible high-risk multiple myeloma patients (ChiCTR2600116772)
    P4, N=117, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P4 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    lenalidomide • bortezomib • Sarclisa (isatuximab-irfc)
    3ms
    ISABELA: Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    dexamethasone • pomalidomide • Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf)
    3ms
    Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=5, Active, not recruiting, OHSU Knight Cancer Institute | Trial primary completion date: Apr 2026 --> Oct 2026
    Trial primary completion date
    |
    carfilzomib • pomalidomide • Sarclisa (isatuximab-irfc)
    4ms
    The real-world safety profile and potential mechanism of isatuximab: Integration of pharmacovigilance and transcriptomic analysis. (PubMed, Medicine (Baltimore))
    By synergizing real-world pharmacovigilance with transcriptomic data, this study delineates novel clinical AE signals and mechanistic insights linking CD38-driven immunometabolic dysregulation to isatuximab toxicity. These findings underscore the imperative for vigilant monitoring and tailored therapeutic strategies to mitigate risks of immune dysfunction, informing both clinical practice and future biomarker-driven interventions.
    Journal • Adverse events • Real-world evidence • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    Sarclisa (isatuximab-irfc)